In-vivo biodistribution and safety of 99mTc-LLP2A-hynic in canine non-hodgkin lymphoma

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Zwingenberger, Allison L ^a   Kent, Michael S ^a   Liu, Ruiwu ^b   Kukis, David L ^c   Wisner, Erik R ^a   DeNardo, Sally J ^d   Taylor, Sandra L ^b   Chen, Xiucui ^b   Lam, Kit S ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; N [[4 [[[(2 ETHYLPHENYL)AMINO]CARBONYL]AMINO]PHENYL]ACETYL] N EPSILON 6 [ 1 OXO 3 (3 PYRIDINYL 2 PROPENYL)] LYSYL 2 AMINOHEXANEDIOYL (1 AMINO 1 CYCLOHEXANE)CARBOXAMIDE HYNIC POLYETHYLENE GLYCOL TC 99M; N [[4 [[[(2 ETHYLPHENYL)AMINO]CARBONYL]AMINO]PHENYL]ACETYL] N EPSILON 6 [ 1 OXO 3 (3 PYRIDINYL 2 PROPENYL)] LYSYL 2 AMINOHEXANEDIOYL (1 AMINO 1 CYCLOHEXANE)CARBOXAMIDE HYNIC TC 99M; PEPTIDOMIMETIC AGENT; PREDNISONE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE; CARBANILAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DIPEPTIDE; LLP2A COMPOUND; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER RADIOTHERAPY; CHEMICAL LABELING; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PURITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; KIDNEY; MOLECULAR IMAGING; MOLECULAR SIZE; NONHODGKIN LYMPHOMA; NONHUMAN; ANIMAL; CHEMISTRY; MOUSE; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

ANIMALS; DIPEPTIDES; DOGS; LYMPHOMA, NON-HODGKIN; MICE; ORGANOTECHNETIUM COMPOUNDS; PHENYLUREA COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84860182457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034404     Document Type: Article

References (25)

1. Jaspars LH, Bonnet P, Bloemena E, Meijer CJ, (1996) Extracellular matrix and beta 1 integrin expression in nodal and extranodal T-cell lymphomas. J Pathol 178: 36-43.
2. Finn WG, Singleton TP, Schnitzer B, Ross CW, Stoolman LM, (2001) Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia. Hum Pathol 32: 66-73.
3. Drillenburg P, Pals ST, (2000) Cell adhesion receptors in lymphoma dissemination. Blood 95: 1900-1910.
4. Holzmann B, Gosslar U, Bittner M, (1998) alpha 4 integrins and tumor metastasis. Current topics in microbiology and immunology 231: 125-141.
5. Davies AJ, (2007) Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 26: 3614-3628.
6. Dillman RO, (2006) Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clinical and experimental medicine 6: 1-12.
7. Williams LE, DeNardo GL, Meredith RF, (2008) Targeted radionuclide therapy. Medical Physics 35: 3062-3068.
8. Reubi JC, Macke HR, Krenning EP, (2005) Candidates for peptide receptor radiotherapy today and in the future. Journal of Nuclear Medicine 46 (Suppl 1): 67S-75S.
9. Peng L, Liu R, Marik J, Wang X, Takada Y, et al. (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against alpha(4)beta(1) integrin for in vivo tumor imaging. Nat Chem Biol 2: 381-389.
10. Blanco E, Kessinger CW, Sumer BD, Gao J, (2009) Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 234: 123-131.
11. Brannon-Peppas L, Blanchette JO, (2004) Nanoparticle and targeted systems for cancer therapy. Advanced drug delivery reviews 56: 1649-1659.
12. Paoloni M, Khanna C, (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156.
13. Vail DM, MacEwen EG, (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792.
14. Denardo SJ, Liu R, Albrecht H, Natarajan A, Sutcliffe JL, et al. (2009) 111In-LLP2A-DOTA polyethylene glycol-targeting {alpha}4{beta}1 integrin: comparative pharmacokinetics for imaging and therapy of lymphoid malignancies. J Nucl Med 50: 625-634.
15. Zwingenberger AL, Kent MS, Shi C, Taylor SL, Chen X, et al. (2011) Affinity of alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma Veterinary Immunology and Immunopathology Submitted.
16. Peng L, Liu R, Andrei M, Xiao W, Lam KS, (2008) In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against alpha4beta1 integrin. Molecular cancer therapeutics 7: 432-437.
17. Bennink RJ, Thurlings RM, van Hemert FJ, Voermans C, Dohmen SE, et al. (2008) Biodistribution and radiation dosimetry of 99mTc-HMPAO-labeled monocytes in patients with rheumatoid arthritis. Journal of Nuclear Medicine 49: 1380-1385.
18. Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, et al. (1996) A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nuclear Medicine and Biology 23: 525-532.
19. DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, et al. (1991) Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Nuclear Medicine And Biology 18: 621-631.
20. Berry CR, (2006) Textbook of veterinary nuclear medicine. Knoxville, TN American College of Veterinary Radiology.
21. DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, et al. (2003) Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res 9: 3854S-3864S.
22. Hamidi M, Azadi A, Rafiei P, (2006) Pharmacokinetic consequences of pegylation. Drug delivery 13: 399-409.
23. Denardo SJ, Liu R, Albrecht H, Natarajan A, Sutcliffe JL, et al. (2009) 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies. J Nucl Med.
24. Wahl RL, (2003) The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 30: 31-38.
25. Padilla L, Lee C, Milner R, Shahlaee A, Bolch WE, (2008) Canine anatomic phantom for preclinical dosimetry in internal emitter therapy. J Nucl Med 49: 446-452.